Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer JClin. 2012;62:10–29.
   PubMed Web of Science ®Google Scholar
• Iversen P, McLeod DG, See WA, et al. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJUInt. 2010;105:1074–1081.
   PubMed Web of Science ®Google Scholar
• Tyrrell CJ, Kaisary AV Iversen P, et al. A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33:447–456.
   PubMed Web of Science ®Google Scholar
• Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and metaanalysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002;95:361–376.
   PubMed Web of Science ®Google Scholar
• Small EJ, Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer. 1995;76:1428–1434.
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–790.
   PubMed Web of Science ®Google Scholar
• Li Y, Chan SC, Brand LJ, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2012;73:483–489.
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375:1437–1446.
   PubMed Web of Science ®Google Scholar
• Higano C, Beer TM, Taplin M, et al. Antitumor activity of MDV3100 in pre- and post-docetaxel advanced prostate cancer: Long-term follow-up of a phase 1–2 study. J Clin Oncol. 2011;29(7):abstract 134.
   Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–1197.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Saad F, et al. Impact of enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study. 37th European Society for Medical Oncology Congress; September 28-October 2, 2012; Vienna, Austria. Abstract 896O.
   Google Scholar
• Scher HI, Fizazi, K, Saad F, et al. Association of baseline corticosteroid with outcomes in a multivariate analysis of the Phase 3 AFFIRM study of enzalutamide (ENZA), an androgen receptor signaling inhibitor. 37th European Society for Medical Oncology Congress; September 28-October 2, 2012. Vienna, Austria. Abstract 899PD.
   Google Scholar
• Li Y, Chan SC, Brand LJ, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73:483–489.
   PubMed Web of Science ®Google Scholar
• Efstathiou E, Titus MA, Tsavachidou A, et al. MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: A preliminary report. J Clin Oncol. 2011;29:abstract 4501.
   Google Scholar
• McCourt C, Maxwell P, Mazzucchelli R, et al. Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor-Targeted Therapy. Clin Cancer Res. 2002;18:3822–3833.
   Google Scholar
• Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509 : a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72:1494–1503.
   PubMed Web of Science ®Google Scholar
• Rathkopf D, Morris MJ, Danila DC, et al. A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2012;30:abstract 4548.
   Google Scholar
• Rathkopf D, Danila DC, Morris M, Slovin S, Scher HI. Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study. J Clin Oncol. 2012;30(5):abstract 43.
   Google Scholar
• Rathkopf D, Shore N, Antonarakis ES, et al. A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol. 2012;30:abstract TPS4697.
   Google Scholar
• Baskin-Bey ES, Shore ND, Barber K, Taoufik O, Heidenreich A. TERRAIN: A randomized, double-blind, phase II study comparing MDV3100 with bicalutamide (Bic) in men with metastatic castrate-resistant prostate cancer (CRPC). J Clin Oncol. 2012;30:abstract TPS4698.
   Google Scholar
• Baskin-Bey ES, Holtkamp GM, Smith MR, et al. A phase II, open-label, single-arm, efficacy, and safety study of MDV3100 in patients with hormone-naïve prostate cancer. J Clin Oncol. 29, 2011;29(7):abstract 177.
   Google Scholar
• Montgomery RB, Joshua A, Hannah AL, et al. A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer. J Clin Oncol. 2012;30: abstract TPS4695.
   Google Scholar
• Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res. 2007;13:2030–2037.
   PubMed Web of Science ®Google Scholar
• Richards J, Lim AC, Hay CW, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012;72:2176–2182.
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242–245.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–1154.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2101;363:411–422.
   Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–148.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich E. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol. 2012;30:abstract LBA4512.
   Google Scholar